On the origin of cancer metastasis

Critical Reviews in Oncogenesis

Volumn 18, Issue 1-2, 2013, Pages 43-73

  Seyfried, Thomas N ^a   Huysentruyt, Leanne C ^a,b  

^a BOSTON COLLEGE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cell fusion; Macrophage; Mitochondria; Myeloid cells; Phagocytosis; Seed and soil; Stem cells; Systemic metastasis; VM mouse; Warburg

Indexed keywords

BEVACIZUMAB; CATHEPSIN; CEDIRANIB; EZRIN; GANGLIOSIDE GM3; HEPCIDIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; NITRIC OXIDE; OSTEOPONTIN; PLATELET DERIVED GROWTH FACTOR; REACTIVE OXYGEN METABOLITE; SCAVENGER RECEPTOR; UVOMORULIN;

ABELSON MURINE LEUKEMIA ONCOVIRUS; ANEMIA; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CANCER CELL; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER STEM CELL; CARCINOGENICITY; CARDIOVASCULAR SYSTEM; CELL FUSION; CELL HYBRIDIZATION; CELL RESPIRATION; CROWN GALL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; GENETIC DAMAGE; GENOMIC INSTABILITY; HEMATOPOIETIC STEM CELL; HUMAN; HYPOTHESIS; IMMUNOSURVEILLANCE; LYMPHATIC SYSTEM; METASTASIS; MITOCHONDRION; MORBIDITY; MORPHOGENESIS; NONHUMAN; PHAGOCYTOSIS; PLANT TUMOR; POINT MUTATION; PRIMARY TUMOR; PRIORITY JOURNAL; STEM CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

CELL ADHESION; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MACROPHAGES; MUTATION; NEOPLASM METASTASIS; NEOPLASMS;

EID: 84875360501     PISSN: 08939675     EISSN: 21626448     Source Type: Journal    
DOI: 10.1615/CritRevOncog.v18.i1-2.40     Document Type: Article

References (270)

1. Tarin D. Cell and tissue interactions in carcinogenesis and metastasis and their clinical significance. Sem Cancer Biol. 2011;21(2):72-82.
2. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nature Rev Cancer. 2002;2(8):563-72.
3. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature Rev Cancer. 2003;3(6):453-8.
4. Welch DR. Defining a cancer metastasis. Amer Assoc Cancer Res. Education Book; 2006. p. 111-5.
5. Lazebnik Y. What are the hallmarks of cancer? Nature Rev Cancer. 2010;10(4):232-3.
6. Tarin D. Comparisons of metastases in different organs: biological and clinical implications. Clin Cancer Res. 2008;14(7):1,923-5.
7. Bacac M, Stamenkovic I. Metastatic cancer cell. Annu Rev Pathol. 2008;3:221-47.
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.
9. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011; 331(6024):1,559-64.
10. Sporn MB. The war on cancer. Lancet. 1996;347(9012):1,377-81.
11. Faguet G. The War on Cancer: An Anatomy of a Failure, A Blueprint for the Future. Dordrecht, The Netherlands: Springer. 2008.
12. Duffy MJ, McGowan PM, Gallagher WM. Cancer invasion and metastasis: changing views. J Pathol. 2008;214(3):283-93.
13. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nature Med. 2006;12(8):895-904.
14. Seyfried TN. Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer. Hoboken: John Wiley & Sons. 2012. 432 p.
15. Shelton LM, Mukherjee P, Huysentruyt LC, Urits I, Rosenberg JA, Seyfried TN. A novel pre-clinical in vivo mouse model for malignant brain tumor growth and invasion. Journal Neuro-oncology. 2010;99(2):165-76.
16. Steeg PS. Heterogeneity of drug target expression among metastatic lesions: lessons from a breast cancer autopsy program. Clin Cancer Res. 2008;14(12):3,643-5.
17. Pawelek JM. Cancer-cell fusion with migratory bone-marrow-derived cells as an explanation for metastasis: new therapeutic paradigms. Future Oncology (London, England). 2008;4(4):449-52.
18. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nature Rev Cancer. 2002;2(6):442-54.
19. Weinberg RA. The Biology of Cancer. New York: Garland Science; 2007. 796 p.
20. Kalluri R. EMT: When epithelial cells decide to become mesenchymal-like cells. J Clin Invest. 2009;119(6):1,417-9.
21. Yokota J. Tumor progression and metastasis. Carcinogenesis. 2000;21(3):497-503.
22. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23-8.
23. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H, Lasorella A, Aldape K, Califano A, Iavarone A. The transcriptional network for mesenchymal transformation of brain tumours. Nature. 2010; 463(7279):318-25.
24. Hart IR. New evidence for tumour embolism as a mode of metastasis. J Pathol. 2009;219(3):275-6.
25. Garber K. Epithelial-to-mesenchymal transition is important to metastasis, but questions remain. J Natl Cancer Inst. 2008;100(4):232-3, 9.
26. Nowell PC. Tumor progression: A brief historical perspective. Semin Cancer Biol. 2002;12(4):261-6.
27. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-67.
28. Huysentruyt LC, Seyfried TN. Perspectives on the mesenchymal origin of metastatic cancer. Cancer Metastasis Rev. 2010;29(4):695-707.
29. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene. 2005;24(50):7,443-54.
30. Martin P, Leibovich SJ. Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol. 2005;15(11):599-607.
31. Powell AE, Anderson EC, Davies PS, Silk AD, Pelz C, Impey S, Wong MH. Fusion between Intestinal Epithelial Cells and Macrophages in a Cancer Context Results in Nuclear Reprogramming. Cancer Res. 2011;71(4):1,497-505.
32. Trosko JE. Review paper: cancer stem cells and cancer nonstem cells: from adult stem cells or from reprogramming of differentiated somatic cells. Vet Pathol. 2009;46(2):176-93.
33. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105-11.
34. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009;138(5):822-9.
35. Sell S, Pierce GB. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest. 1994;70(1):6-22.
36. Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL, Black KL, Yu JS. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene. 2004;23(58):9,392-400.
37. Seyfried TN. Perspectives on brain tumor formation involving macrophages, glia, and neural stem cells. Perspect Biol Med. 2001;44(2):263-82.
38. Binello E, Qadeer ZA, Kothari HP, Emdad L, Germano IM. Stemness of the CT-2A immunocompetent mouse brain tumor model: Characterization in vitro. J Cancer. 2012;3:166-74.
39. Huysentruyt LC, Mukherjee P, Banerjee D, Shelton LM, Seyfried TN. Metastatic cancer cells with macrophage properties: Evidence from a new murine tumor model. Inter J Cancer. 2008;123(1):73-84.
40. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144(5):646-74.
41. Siebzehnrubl FA, Reynolds BA, Vescovi A, Steindler DA, Deleyrolle LP. The origins of glioma: E Pluribus Unum? Glia. 2011;59(8):1,135-47.
42. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66(2):605-12.
43. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nature Rev Cancer. 2009;9(4):239-52.
44. Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J of Leukocyte Biol. 2008;84(3):623-30.
45. Morantz RA, Wood GW, Foster M, Clark M, Gollahon K. Macrophages in experimental and human brain tumors. Part 2: studies of the macrophage content of human brain tumors. J Neurosurg. 1979;50(3):305-11.
46. Biswas SK, Sica A, Lewis CE. Plasticity of macrophage function during tumor progression: Regulation by distinct molecular mechanisms. J Immunol. 2008;180(4):2,011-7.
47. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996;56(20):4,625-9.
48. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549-55.
49. di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK. Glioblastoma recurrence after cediranib therapy in patients: Lack of "rebound" revascularization as mode of escape. Cancer Res. 2011;71(1):19-28.
50. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39-51.
51. Hanahan D, Coussens LM. Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309-22.
52. Peinado H, Rafii S, Lyden D. Inflammation joins the "niche. " Cancer Cell. 2008;14(5):347-9.
53. Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 2007;26(3-4):373-400
54. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196(3):254-65.
55. Huysentruyt LC, Akgoc Z, Seyfried TN. Hypothesis: are neoplastic macrophages/microglia present in glioblastoma multiforme? ASNNeuro. 2011;3(4):art:e00064. doi:10.1042/AN20110011.
56. Maniecki MB, Etzerodt A, Ulhoi BP, Steiniche T, Borre M, Dyrskjot L, Orntoft TF, Moestrup SK, Moller HJ. Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Inter J Cancer. 2012. Epub 2012/03/01.
57. Navarro A, Boveris A. Hypoxia exacerbates macrophage mitochondrial damage in endotoxic shock. Am J Physiol Regul Integr Comp Physiol. 2005;288(2):R354-5.
58. Frost MT, Wang Q, Moncada S, Singer M. Hypoxia accelerates nitric oxide-dependent inhibition of mitochondrial complex I in activated macrophages. Am J Physiol Regul Integr Comp Physiol. 2005;288(2):R394-400.
59. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1,029-33.
60. Pawelek JM. Tumour cell hybridization and metastasis revisited. Melanoma Res. 2000;10(6):507-14.
61. Seyfried TN, Shelton LM, Mukherjee P. Does the existing standard of care increase glioblastoma energy metabolism? Lancet Oncol. 2010;11(9):811-3.
62. Munzarova M, Kovarik J. Is cancer a macrophage-mediated autoaggressive disease? Lancet. 1987;1(8539):952-4.
63. Vignery A. Macrophage fusion: Are somatic and cancer cells possible partners? Trends Cell Biol. 2005;15(4):188-93.
64. Chakraborty AK, de Freitas Sousa J, Espreafico EM, Pawelek JM. Human monocyte x mouse melanoma fusion hybrids express human gene. Gene. 2001;275(1):103-6.
65. Van den Bossche J, Bogaert P, van Hengel J, Guerin CJ, Berx G, Movahedi K, Van den Bergh R, Pereira-Fernandes A, Geuns JM, Pircher H, Dorny P, Grooten J, De Baetselier P, Van Ginderachter JA. Alternatively activated macrophages engage in homotypic and heterotypic interactions through IL-4 and polyamine-induced E-cadherin/catenin complexes. Blood. 2009;114(21):4,664-74.
66. Pawelek JM. Tumour-cell fusion as a source of myeloid traits in cancer. Lancet Oncol. 2005;6(12):988-93.
67. Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, Prinz M, Wu B, Jacobsen SE, Pollard JW, Frampton J, Liu KJ, Geissmann F. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science. 2012;336(6077):86-90. Epub 2012/03/24.
68. Seyfried TN, El-Abbadi M, Ecsedy JA, Bai HW, Yohe HC. Influence of host cell infiltration on the glycolipid content of mouse brain tumors. J Neurochem. 1996;66(5):2,026-33.
69. Ecsedy JA, Yohe HC, Bergeron AJ, Seyfried TN. Tumor-infiltrating macrophages influence the glycosphingolipid composition of murine brain tumors. J Lipid Res. 1998;39(11):2,218-27.
70. Goldenberg DM. Horizontal transmission of malignancy by cell-cell fusion. Expert Opin Biol Ther. 2012. Epub 2012/04/17.
71. Stossel TP. Mechanical responses of white blood cells. In: Snyderman JIGaR, editor. Inflammation: Basic Principles and Clinical Correlates. New York: Lippincott Williams & Wilkins; 1999. p. 661-79.
72. Gordon S. Development and distribution of mononuclear phagocytes: Relevance to inflammation. In: Gallin JI, Snyderman R, editors. Inflammation: Basic Principles and Clinical Correlates. New York: Lippincott Williams & Wilkins; 1999. p. 35-48.
73. Burke B, Lewis CE. The Macrophage. 2nd ed. New York: Oxford University Press; 2002.
74. Sica A, Saccani A, Mantovani A. Tumor-associated macrophages: A molecular perspective. Int Immunopharmacol. 2002;2(8):1,045-54.
75. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42(6):717-27.
76. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889-96.
77. Gordon S, Martinez FO. Alternative activation of macrophages: Mechanism and functions. Immunity. 2003;32(5):593-604.
78. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22(2):231-7.
79. Underhill CB, Nguyen HA, Shizari M, Culty M. CD44 positive macrophages take up hyaluronan during lung development. Develop Biology. 1993;155(2):324-36.
80. Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Amer J Pathol. 1998;152(2):353-8.
81. Culty M, O'Mara TE, Underhill CB, Yeager H, Jr., Swartz RP. Hyaluronan receptor (CD44) expression and function in human peripheral blood monocytes and alveolar macrophages. J Leukocyte Biol. 1994;56(5):605-11.
82. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukocyte Biol. 1994;55(3):410-22.
83. Chettibi S, Ferguson MWJ. Wound repair: An overview. In: Snyderman JIGaR, editor. Inflamation: Basic Principles and Clinical Correlates. New York: Lippincott Williams & Wilkins; 1999. p. 865-81.
84. Sica A, Mantovani A. Macrophage fusion cuisine. Blood. 2009;114(21):4,609-10.
85. Vignery A. Osteoclasts and giant cells: macrophage-macrophage fusion mechanism. International J Exper Patholo. 2000;81(5):291-304.
86. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005;6(12):1,191-7.
87. Bellingan GJ, Caldwell H, Howie SE, Dransfield I, Haslett C. In vivo fate of the inflammatory macrophage during the resolution of inflammation: Inflammatory macrophages do not die locally, but emigrate to the draining lymph nodes. J Immunol. 1996;157(6):2,577-85.
88. Randolph GJ, Inaba K, Robbiani DF, Steinman RM, Muller WA. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity. 1999;11(6):753-61.
89. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006;25(3):315-22.
90. Akst J. It's a cell-eat-cell world. The Scientist. 2011;25(August):44-9.
91. Fais S. Cannibalism: a way to feed on metastatic tumors. Cancer Letters. 2007;258(2):155-64.
92. Wang S, Guo Z, Xia P, Liu T, Wang J, Li S, Sun L, Lu J, Wen Q, Zhou M, Ma L, Ding X, Wang X, Yao X. Internalization of NK cells into tumor cells requires ezrin and leads to programmed cell-in-cell death. Cell Res. 2009;19(12):1,350-62.
93. Lugini L, Matarrese P, Tinari A, Lozupone F, Federici C, Iessi E, Gentile M, Luciani F, Parmiani G, Rivoltini L, Malorni W, Fais S. Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res. 2006;66(7):3,629-38.
94. Couzin-Frankel J. Immune therapy steps up the attack. Science. 2010;330(6003):440-3.
95. Klionsky DJ. Cell biology: regulated self-cannibalism. Nature. 2004;431(7004):31-2.
96. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature. 2008;451(7182):1,069-75.
97. Hoffman HJ, Duffner PK. Extraneural metastases of central nervous system tumors. Cancer. 1985;56(7 Suppl):1,778-82.
98. Taha M, Ahmad A, Wharton S, Jellinek D. Extra-cranial metastasis of glioblastoma multiforme presenting as acute parotitis. Br J Neurosurg. 2005;19(4):348-51.
99. Laerum OD, Bjerkvig R, Steinsvag SK, de Ridder L. Invasiveness of primary brain tumors. Cancer Metastasis Rev. 1984;3(3):223-36.
100. Rubinstein LJ. Tumors of the central nervous system. Washington, D.C.: Armed Forces Institute of Pathology; 1972. 400 p.
101. Gotway MB, Conomos PJ, Bremner RM. Pleural Metastatic Disease From Glioblastoma Multiforme. J Thorac Imaging. 2011;26(2):W54-8.
102. Kalokhe G, Grimm SA, Chandler JP, Helenowski I, Rademaker A, Raizer JJ. Metastatic glioblastoma: case presentations and a review of the literature. J Neuro-Oncol. 2012;107(1):21-7.
103. Armanios MY, Grossman SA, Yang SC, White B, Perry A, Burger PC, Orens JB. Transmission of glioblastoma multiforme following bilateral lung transplantation from an affected donor: case study and review of the literature. Neuro-oncology. 2004;6(3):259-63.
104. Ng WH, Yeo TT, Kaye AH. Spinal and extracranial metastatic dissemination of malignant glioma. J Clin Neurosci. 2005;12(4):379-82.
105. Strojnik T, Kavalar R, Zajc I, Diamandis EP, Oikonomopoulou K, Lah TT. Prognostic impact of CD68 and kallikrein 6 in human glioma. Anticancer Res. 2009;29(8):3,269-79.
106. Duffy PE. Astrocytes: Normal, Reactive, and Neoplastic. New York: Raven Press; 1983. 224 p.
107. Han SJ, Yang I, Otero JJ, Ahn BJ, Tihan T, McDermott MW, Berger MS, Chang SM, Parsa AT. Secondary gliosarcoma after diagnosis of glioblastoma: Clinical experience with 30 consecutive patients. J Neurosurg. 2010 May; 112(5):990-6.
108. Scherer HJ. A critical review: The pathology of cerebral gliomas. J Neurol Neuropsychiat. 1940;3:147-77.
109. Tso CL, Shintaku P, Chen J, Liu Q, Liu J, Chen Z, Yoshimoto K, Mischel PS, Cloughesy TF, Liau LM, Nelson SF. Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res. 2006;4(9):607-19.
110. Fan X, Salford LG, Widegren B. Glioma stem cells: Evidence and limitation. Sem Cancer Biol. 2007;17(3):214-8.
111. Yates AJ. An overview of principles for classifying brain tumors. Mol Chem Neuropathol. 1992;17(2):103-20.
112. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-oncology. 2010;12(3):233-42.
113. Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, DeAngelis LM, Lassman AB. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology. 2009;73(15):1,200-6.
114. Molad Y, Stark P, Prokocimer M, Joshua H, Pinkhas J, Sidi Y. Hemophagocytosis by small cell lung carcinoma. Am J Hematol. 1991;36(2):154-6.
115. Khayyata S, Basturk O, Adsay NV. Invasive micropapillary carcinomas of the ampullopancreatobiliary region and their association with tumor-infiltrating neutrophils. Mod Pathol.2005;18(11):1,504-11.
116. Bjerknes R, Bjerkvig R, Laerum OD. Phagocytic capacity of normal and malignant rat glial cells in culture. J Natl Cancer Inst. 1987;78(2):279-88.
117. Youness E, Barlogie B, Ahearn M, Trujillo JM. Tumor cell phagocytosis. Its occurrence in a patient with medulloblastoma. Arch Pathol Lab Med. 1980;104(12):651-3.
118. Ghoneum M, Gollapudi S. Phagocytosis of Candida albicans by metastatic and non metastatic human breast cancer cell lines in vitro. Cancer Detect. Prev. 2004;28(1):17-26.
119. Marin-Padilla M. Erythrophagocytosis by epithelial cells of a breast carcinoma. Cancer. 1977;39(3):1,085-9.
120. Spivak JL. Phagocytic tumour cells. Scand J Haematol. 1973;11(3):253-6.
121. Falini B, Bucciarelli E, Grignani F, Martelli MF. Erythrophagocytosis by undifferentiated lung carcinoma cells. Cancer. 1980;46(5):1,140-5.
122. Lugini L, Lozupone F, Matarrese P, Funaro C, Luciani F, Malorni W, Rivoltini L, Castelli C, Tinari A, Piris A, Parmiani G, Fais S. Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: A key role of ezrin. Lab Invest. 2003;83(11):1,555-67.
123. Wu JM, Fackler MJ, Halushka MK, Molavi DW, Taylor ME, Teo WW, Griffin C, Fetting J, Davidson NE, De Marzo AM, Hicks JL, Chitale D, Ladanyi M, Sukumar S, Argani P. Heterogeneity of breast cancer metastases: Comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res. 2008;14(7):1,938-46.
124. Abodief WT, Dey P, Al-Hattab O. Cell cannibalism in ductal carcinoma of breast. Cytopathology. 2006;17(5):304-5.
125. Kerbel RS, Lagarde AE, Dennis JW, Donaghue TP. Spontaneous fusion in vivo between normal host and tumor cells: possible contribution to tumor progression and metastasis studied with a lectin-resistant mutant tumor. Mol Cell Biol. 1983;3(4):523-38.
126. Kerbel RS, Twiddy RR, Robertson DM. Induction of a tumor with greatly increased metastatic growth potential by injection of cells from a low-metastatic H-2 heterozygous tumor cell line into an H-2 incompatible parental strain. Inter J Cancer. 1978;22(5):583-94.
127. Seyfried TN, Mukherjee P. Ganglioside GM3 is antiangiogenic in malignant brain cancer. J Oncol. 2010;2010:961243.
128. Chen EH, Grote E, Mohler W, Vignery A. Cell-cell fusion. FEBS Lett. 2007; 581(11):2,181-93.
129. Camargo FD, Chambers SM, Goodell MA. Stem cell plasticity: from transdifferentiation to macrophage fusion. Cell Prolif. 2004;37(1):55-65.
130. Camargo FD, Finegold M, Goodell MA. Hematopoietic myelomonocytic cells are the major source of hepatocyte fusion partners. J Clin Invest. 2004;113(9):1,266-70.
131. Paris S, Sesboue R. Metastasis models: the green fluorescent revolution? Carcinogenesis. 2004;25(12):2,285-92.
132. Duelli D, Lazebnik Y. Cell fusion: A hidden enemy? Cancer Cell. 2003;3(5):445-8.
133. Mekler LB, Drize OB, Osechinskii IV, Shliankevich MA. [Transformation of a normal differentiated cell of an adult organism, induced by the fusion of this cell with another normal cell of the same organism but with different organ or tissue specificity]. Vestn Akad Med Nauk USSR. 1971;26(4):75-80.
134. Warner TF. Cell hybridizaiton: An explanation for the phenotypic diversity of certain tumours. Med Hypoth. 1975;1(1):51-7.
135. Levin TG, Powell AE, Davies PS, Silk AD, Dismuke AD, Anderson EC, Swain JR, Wong MH. Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract. Gastroenterology. 2010;139(6):2,072-82 e5.
136. Seyfried TN, Kiebish MA, Marsh J, Shelton LM, Huysentruyt LC, Mukherjee P. Metabolic management of brain cancer. Biochim Biophysic Acta. 2010;1807(6):577-94.
137. Shabo I, Olsson H, Sun XF, Svanvik J. Expression of the macrophage antigen CD163 in rectal cancer cells is associated with early local recurrence and reduced survival time. Inter J Cancer. 2009;125(8):1,826-31.
138. Shabo I, Stal O, Olsson H, Dore S, Svanvik J. Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Inter J Cancer. 2008;123(4):780-6.
139. Rachkovsky M, Pawelek J. Acquired melanocyte stimulating hormone-inducible chemotaxis following macrophage fusion with Cloudman S91 melanoma cells. Cell Growth Differ. 1999;10(7):517-24.
140. Handerson T, Camp R, Harigopal M, Rimm D, Pawelek J. Beta1,6-branched oligosaccharides are increased in lymph node metastases and predict poor outcome in breast carcinoma. Clin Cancer Res. 2005;11(8):2,969-73.
141. Chakraborty AK, Sodi S, Rachkovsky M, Kolesnikova N, Platt JT, Bolognia JL, Pawelek JM. A spontaneous murine melanoma lung metastasis comprised of host x tumor hybrids. Cancer Res. 2000;60(9):2,512-9.
142. Yilmaz Y, Lazova R, Qumsiyeh M, Cooper D, Pawelek J. Donor Y chromosome in renal carcinoma cells of a female BMT recipient: Visualization of putative BMT-tumor hybrids by FISH. Bone Marrow Transplant. 2005;35(10):1,021-4.
143. Chakraborty A, Lazova R, Davies S, Backvall H, Ponten F, Brash D, Pawelek J. Donor DNA in a renal cell carcinoma metastasis from a bone marrow transplant recipient. Bone Marrow Transplant. 2004;34(2):183-6.
144. Pawelek JM, Chakraborty AK. The cancer cell--leukocyte fusion theory of metastasis. Adv Cancer Res. 2008;101:397-444.
145. Goldenberg DM, Pavia RA, Tsao MC. In vivo hybridisation of human tumour and normal hamster cells. Nature. 1974;250(5468):649-51.
146. Munzarova M, Lauerova L, Capkova J. Are advanced malignant melanoma cells hybrids between melanocytes and macrophages? Melanoma Res. 1992;2(2):127-9.
147. Busund LT, Killie MK, Bartnes K, Seljelid R. Spontaneously formed tumorigenic hybrids of Meth A sarcoma cells and macrophages in vivo. Inter J Cancer. 2003;106(2):153-9.
148. Ades L, Guardiola P, Socie G. Second malignancies after allogeneic hematopoietic stem cell transplantation: new insight and current problems. Blood Rev. 2002;16(2):135-46.
149. Tebeu P-M, Verkooijen HM, Bouchardy C, Ludicke F, Usel M, Major AL. Impact of external radiotherapyon survivalafter stage I endometrial cancer: Results from a population based study. J Cancer Sci Ther. 2011;3(2):41-6.
150. Pawelek JM, Chakraborty AK. Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis. Nature Rev Cancer. 2008;8(5):377-86.
151. Guillemin GJ, Brew BJ. Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J Leukocyte Biol. 2004;75(3):388-97.
152. Ruff MR, Pert CB. Small cell carcinoma of the lung: macrophage-specific antigens suggest hemopoietic stem cell origin. Science. 1984;225(4666):1,034-6.
153. Calvo F, Martin PM, Jabrane N, De Cremoux P, Magdelenat H. Human breast cancer cells share antigens with the myeloid monocyte lineage. Brit J Cancer. 1987;56(1):15-9.
154. Gazdar AF, Bunn PA, Jr., Minna JD, Baylin SB. Origin of human small cell lung cancer. Science. 1985;229(4714):679-80.
155. Ruff MR, Pert CB. Origin of human small cell lung cancer. Science. 1985;229(4714):680.
156. Bunn PA, Jr., Linnoila I, Minna JD, Carney D, Gazdar AF. Small cell lung cancer, endocrine cells of the fetal bronchus, and other neuroendocrine cells express the Leu-7 antigenic determinant present on natural killer cells. Blood. 1985;65(3):764-8.
157. Davies PS, Powell AE, Swain JR, Wong MH. Inflammation and proliferation act together to mediate intestinal cell fusion. PloS one. 2009;4(8):e6,530.
158. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, Thorsen F, Taxt T, Bartos M, Jirik R, Miletic H, Wang J, Stieber D, Stuhr L, Moen I, Rygh CB, Bjerkvig R, Niclou SP. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci. 2011;108(9):3,749-54.
159. Diment S, Leech MS, Stahl PD. Cathepsin D is membrane-associated in macrophage endosomes. J Biol Chem. 1988;263(14):6,901-7.
160. Stehle G, Sinn H, Wunder A, Schrenk HH, Stewart JC, Hartung G, Maier-Borst W, Heene DL. Plasma protein (albumin) catabolism by the tumor itself--implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol. 1997;26(2):77-100.
161. Moon Y, Kim JY, Choi SY, Kim K, Kim H, Sun W. Induction of ezrin-radixin-moesin molecules after cryogenic traumatic brain injury of the mouse cortex. Neuroreport. 2011;22(6):304-8.
162. Fehon RG, McClatchey AI, Bretscher A. Organizing the cell cortex: The role of ERM proteins. Nat Rev Mol Cell Biol. 2010;11(4):276-87.
163. Krishnan K, Bruce B, Hewitt S, Thomas D, Khanna C, Helman LJ. Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clinical Exper Metastasis. 2006;23(3-4):227-36.
164. Park HR, Cabrini RL, Araujo ES, Paparella ML, Brandizzi D, Park YK. Expression of ezrin and metastatic tumor antigen in osteosarcomas of the jaw. Tumori. 2009;95(1):81-6.
165. Fais S. A role for ezrin in a neglected metastatic tumor function. Trends Molec Med. 2004;10(6):249-50.
166. Hunter KW. Ezrin, a key component in tumor metastasis. Trends Molec Med. 2004;10(5):201-4.
167. Bobryshev YV, Lord RS, Watanabe T, Ikezawa T. The cell adhesion molecule E-cadherin is widely expressed in human atherosclerotic lesions. Cardiovas Res. 1998;40(1):191-205.
168. Armeanu S, Buhring HJ, Reuss-Borst M, Muller CA, Klein G. E-cadherin is functionally involved in the maturation of the erythroid lineage. J Cell Biol. 1995;131(1):243-9.
169. Ward DG, Roberts K, Brookes MJ, Joy H, Martin A, Ismail T, Spychal R, Iqbal T, Tselepis C. Increased hepcidin expression in colorectal carcinogenesis. World J Gastroenterol. 2008;14(9):1,339-45.
170. Leonard RC, Untch M, Von Koch F. Management of anaemia in patients with breast cancer: role of epoetin. Ann Oncol. 2005;16(5):817-24.
171. Kamai T, Tomosugi N, Abe H, Arai K, Yoshida K. Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma. BMC Cancer. 2009;9:270.
172. Ganz T. Hepcidin--a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol. 2005;18(2):171-82.
173. Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol. 2009;69(3):271-8.
174. Carlson HR. Carcinoma of unknown primary: searching for the origin of metastases. Jaapa. 2009;22(8):18-21.
175. Heidemann J, Gockel HR, Winde G, Herbst H, Domschke W, Lugering N. Signet-ring cell carcinoma of unknown primary location. Metastatic to lower back musculature-remission following FU/FA chemotherapy. Z Gastroenterol. 2002;40(1):33-6.
176. Hedley DW, Leary JA, Kirsten F. Metastatic adenocarcinoma of unknown primary site: abnormalities of cellular DNA content and survival. Eur J Cancer Clin Oncol. 1985;21(2):185-9.
177. Torres EM, Williams BR, Tang YC, Amon A. Thoughts on aneuploidy. Cold Spring Harbor Symposia on Quantitative Biology. 2010;75:445-51.
178. Torres EM, Williams BR, Amon A. Aneuploidy: cells losing their balance. Genetics. 2008;179(2):737-46.
179. Rizvi AZ, Swain JR, Davies PS, Bailey AS, Decker AD, Willenbring H, Grompe M, Fleming WH, Wong MH. Bone marrow-derived cells fuse with normal and transformed intestinal stem cells. Proc Natl Acad Sci USA. 2006;103(16):6,321-5.
180. Lazova R, Chakraborty A, Pawelek JM. Leukocyte-cancer cell fusion: Initiator of the Warburg effect in malignancy? Adv Exper Med Biol. 2011;714:151-72.
181. Seyfried TN, Shelton LM. Cancer as a metabolic disease. Nutrit & Metabol. 2010;7(1):7.
182. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-14.
183. Warburg O. On the respiratory impairment in cancer cells. Science. 1956;124:269-70.
184. Carew JS, Huang P. Mitochondrial defects in cancer. Mol Cancer. 2002;1:9.
185. Pedersen PL. Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res. 1978;22:190-274.
186. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol. 2009;27:669-92.
187. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;1:571-3.
188. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal SA, Leroy C, Jia M, Menzies A, Butler AP, Teague Jw, Griffin CA, Burton J, Swerdlow H, Quail MA, Stratton MR, Iacobuzio-Donahue C, Futreal PA. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010;467(7319):1,109-13.
189. Kennedy DW, Abkowitz JL. Mature monocytic cells enter tissues and engraft. Proc Natl Acad Sci USA. 1998;95(25):14,944-9.
190. Klein I, Cornejo JC, Polakos NK, John B, Wuensch SA, Topham DJ, Pierce RH, Crispe IN. Kupffer cell heterogeneity: Functional properties of bone marrow derived and sessile hepatic macrophages. Blood. 2007;110(12):4,077-85.
191. Hofer SO, Molema G, Hermens RA, Wanebo HJ, Reichner JS, Hoekstra HJ. The effect of surgical wounding on tumour development. Eur J Surg Oncol. 1999;25(3):231-43.
192. Soto AM, Sonnenschein C. The somatic mutation theory of cancer: Growing problems with the paradigm? Bioessays. 2004;26(10):1,097-107.
193. Hirshberg A, Leibovich P, Horowitz I, Buchner A. Metastatic tumors to postextraction sites. J Oral Maxillofac Surg. 1993;51(12):1,334-7.
194. Cho E, Kim MH, Cha SH, Cho SH, Oh SJ, Lee JD. Breast cancer cutaneous metastasis at core needle biopsy site. Ann Dermatol. 2010;22(2):238-40.
195. Hirshberg A, Leibovich P, Buchner A. Metastases to the oral mucosa: analysis of 157 cases. J Oral Pathol Med. 1993;22(9):385-90.
196. Jones FS, Rous P. On the Cause of the localization of secondary tumors at points of Injury. J Exp Med. 1914;20(4):404-12.
197. Walter ND, Rice PL, Redente EF, Kauvar EF, Lemond L, Aly T, Wanebo K, Chan ED. Wound healing after trauma may predispose to lung cancer metastasis: Review of potential mechanisms. Am J Respir Cell Mol Biol. 2011;44(5):591-6.
198. Willenbring H, Bailey AS, Foster M, Akkari Y, Dorrell C, Olson S, Finegold M, Fleming WH, Grompe M. Myelomonocytic cells are sufficient for therapeutic cell fusion in liver. Nat Med. 2004;10(7):744-8.
199. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1,801-6.
200. Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 2009;100(12):2,235-41.
201. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1,807-12.
202. Salk JJ, Fox EJ, Loeb LA. Mutational heterogeneity in human cancers: Origin and consequences. Annu Rev Pathol. 2010;5:51-75.
203. Park MS, Kim Y, Kang MS, Oh SY, Cho DY, Shin NS, Kim DY. Disseminated transmissible venereal tumor in a dog. J Vet Diagn Invest. 2006;18(1):130-3.
204. Murchison EP, Tovar C, Hsu A, Bender HS, Kheradpour P, Rebbeck CA, Obendorf D, Conlan C, Bahlo M, Blizzard CA, Pyecroft S, Kreiss A, Kellis M, Stark A, Harkins TT, Marshall Graves JA, Woods GM, Hannon GJ, Papenfuss AT. The Tasmanian devil transcriptome reveals Schwann cell origins of a clonally transmissible cancer. Science. 2010;327(5961):84-7.
205. Mozos E, Mendez A, Gomez-Villamandos JC, Martin De Las Mulas J, Perez J. Immunohistochemical characterization of canine transmissible venereal tumor. Vet Pathol. 1996;33(3):257-63.
206. Marchal T, Chabanne L, Kaplanski C, Rigal D, Magnol JP. Immunophenotype of the canine transmissible venereal tumour. Vet Immunol Immunopathol. 1997;57(1-2):1-11.
207. Zhao FQ, Zhang PX, He XJ, Du C, Fu ZG, Zhang DY, Jiang BG. Study on the adoption of Schwann cell phenotype by bone marrow stromal cells in vitro and in vivo. Biomed Environ Sci. 2005;18(5):326-33.
208. Rebbeck CA, Leroi AM, Burt A. Mitochondrial capture by a transmissible cancer. Science. 2011;331(6015):303.
209. Robinson W. Some features of crown-gall in plants in reference to comparisons with cancer. Proc Roy Soc Med. 1927;20:1,507-9.
210. Nester EW, Gordon MP, Amasino RM. Crown gall: A molecular and physiological analysis. Ann Rev Plant Physiol. 1984;35:387-413.
211. Levine M. Plant tumores and their relationship to cancer. Botanical Rev. 1936;2:439-55.
212. Tamaoki T, Hildebrandt AC, Burris RH, Riker AJ, Hagihara B. Respiration and phosphorylation of mitochondria from normal and crown-gall tissue cultures of tomato. Plant Physiol. 1960;35(6):942-7.
213. Klein RM. Nitrogen and Phosphorus Fractions, Respiration, and structure of normal and crown gall tissues of tomato. Plant Physiol. 1952;27(2):335-54.
214. Fogelberg SO, Struckmeyer E, Roberts RH. Morphological variations of mitochondria in the presence of plant tumors. Amer J Botany. 1957;44(5):454-9.
215. Jones JD, Dangl JL. The plant immune system. Nature. 2006;444(7117):323-9.
216. Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: A comprehensive review. Front Pharmacol. 2011;2:49.
217. Marsh J, Mukherjee P, Seyfried TN. Drug/diet synergy for managing malignant astrocytoma in mice: 2-deoxy-D-glucose and the restricted ketogenic diet. Nutrit & Metabol. 2008;5:33.
218. Marsh J, Mukherjee P, Seyfried TN. Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma. Clin. Cancer Res. 2008;14(23):7,751-62.
219. Newsholme P, Lima MM, Procopio J, Pithon-Curi TC, Doi SQ, Bazotte RB, Curi R. Glutamine and glutamate as vital metabolites. Braz J Med Biol Res. 2003;36(2):153-63.
220. Newsholme P. Why is L-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection? J Nutrition. 2001;131(9 Suppl):2515S-22S; Discussion 23S-4S.
221. Shelton LM, Huysentruyt LC, Seyfried TN. Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model. Inter J Cancer. 2010;127(10):2,478-85
222. Shelton LM, Huysentruyt LC, Mukherjee P, Seyfried TN. Calorie restriction as an anti-invasive therapy for malignant brain cancer in the VM mouse. ASN Neuro. 2010;2(3):e00038.
223. Huysentruyt LC, Shelton LM, Seyfried TN. Influence of methotrexate and cisplatin on tumor progression and survival in the VM mouse model of systemic metastatic cancer. Inter J Cancer. 2010;126(1):65-72.
224. Kojima S, Sekine H, Fukui I, Ohshima H. Clinical significance of "cannibalism" in urinary cytology of bladder cancer. Acta Cytol. 1998;42(6):1,365-1,369.
225. Zimmer C, Weissleder R, Poss K, Bogdanova A, Wright SC, Jr., Enochs WS. MR imaging of phagocytosis in experimental gliomas. Radiology. 1995;197(2):533-8.
226. van Landeghem FK, Maier-Hauff K, Jordan A, Hoffmann KT, Gneveckow U, Scholz R, Thiesen B, Bruck W, von Deimling A. Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. Biomaterials. 2009;30(1):52-7.
227. Persson A, Englund E. The glioma cell edge--winning by engulfing the enemy? Med Hypotheses. 2009;73(3):336-7.
228. Nitta T, Okumura K, Sato K. Lysosomal enzymic activity of astroglial cells. Pathobiology. 1992;60(1):42-4.
229. Chang GH, Barbaro NM, Pieper RO. Phosphatidylserine-dependent phagocytosis of apoptotic glioma cells by normal human microglia, astrocytes, and glioma cells. Neuro-oncology. 2000;2(3):174-83.
230. Jeyakumar M, Norflus F, Tifft CJ, Cortina-Borja M, Butters TD, Proia RL, Perry VH, Dwek RA, Platt FM. Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood. 2001;97(1):327-9.
231. Leenstra S, Das PK, Troost D, de Boer OJ, Bosch DA. Human malignant astrocytes express macrophage phenotype. J Neuroimmunol. 1995;56(1):17-25 issn: 0165-5728.
232. Takeuchi H, Kubota T, Kitai R, Nakagawa T, Hashimoto N. CD98 immunoreactivity in multinucleated giant cells of glioblastomas: An immunohistochemical double labeling study. Neuropathology. 2008;28(2):127-31.
233. Deininger MH, Meyermann R, Trautmann K, Morgalla M, Duffner F, Grote EH, Wickboldt J, Schluesener HJ. Cyclooxygenase (COX)-1 expressing macrophages/microglial cells and COX-2 expressing astrocytes accumulate during oligodendroglioma progression. Brain Res. 2000;885(1):111-6.
234. Ghoneum M, Matsuura M, Braga M, Gollapudi S. S. cerevisiae induces apoptosis in human metastatic breast cancer cells by altering intracellular Ca2+ and the ratio of Bax and Bcl-2. International Journal of Oncology. 2008;33(3):533-9.
235. Coopman PJ, Do MT, Thompson EW, Mueller SC. Phagocytosis of cross-linked gelatin matrix by human breast carcinoma cells correlates with their invasive capacity. Clin Cancer Res. 1998;4(2):507-15.
236. Ghoneum M, Wang L, Agrawal S, Gollapudi S. Yeast therapy for the treatment of breast cancer: a nude mice model study. In Vivo. 2007;21(2):251-8.
237. Berx G, Raspe E, Christofori G, Thiery JP, Sleeman JP. Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clinical & Exper Metastasis. 2007;24(8):587-97.
238. Bjerregaard B, Holck S, Christensen IJ, Larsson LI. Syncytin is involved in breast cancer-endothelial cell fusions. Cell Mol Life Sci. 2006;63(16):1,906-11.
239. Atladottir HO, Pedersen MG, Thorsen P, Mortensen PB, Deleuran B, Eaton WW, Parner ET. Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics. 2009;124(2):687-94.
240. Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg. 1988;68(6):835-53.
241. Athanasou NA, Wells CA, Quinn J, Ferguson DP, Heryet A, McGee JO. The origin and nature of stromal osteoclast-like multinucleated giant cells in breast carcinoma: implications for tumour osteolysis and macrophage biology. Brit J Cancer. 1989;59(4):491-8.
242. Acebo P, Giner D, Calvo P, Blanco-Rivero A, Ortega AD, Fernandez PL, Roncador G, Fernandez-Malave E, Chamorro M, Cuezva JM. Cancer abolishes the tissue type-specific differences in the phenotype of energetic metabolism. Transl Oncol. 2009;2(3):138-45.
243. Chandrasoma P. Polymorph phagocytosis by cancer cells in an endometrial adenoacanthoma. Cancer. 1980;45(9):2,348-51.
244. Caruso RA, Muda AO, Bersiga A, Rigoli L, Inferrera C. Morphological evidence of neutrophil-tumor cell phagocytosis (cannibalism) in human gastric adenocarcinomas. Ultrastruct Pathol. 2002;26(5):315-21.
245. Hu J, La Vecchia C, Negri E, Chatenoud L, Bosetti C, Jia X, Liu R, Huang G, Bi D, Wang C. Diet and brain cancer in adults: a case-control study in northeast China. Inter J Cancer. 1999;81(1):20-3.
246. DeSimone PA, East R, Powell RD, Jr. Phagocytic tumor cell activity in oat cell carcinoma of the lung. Hum Pathol. 1980;11(5 Suppl):535-9.
247. Richters A, Sherwin RP, Richters V. The lymphocyte and human lung cancers. Cancer Res. 1971;31(3):214-22.
248. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, Thomas-Tikhonenko A, Thompson CB. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest. 2007;117(2):326-36.
249. Radosevic K, van Leeuwen AM, Segers-Nolten IM, Figdor CG, de Grooth BG, Greve J. Occurrence and a possible mechanism of penetration of natural killer cells into K562 target cells during the cytotoxic interaction. Cytometry. 1995;20(4):273-80.
250. Koren HS, Handwerger BS, Wunderlich JR. Identification of macrophage-like characteristics in a cultured murine tumor line. J Immunol. 1975;114(2 pt 2):894-7.
251. Larizza L, Schirrmacher V, Pfluger E. Acquisition of high metastatic capacity after in vitro fusion of a nonmetastatic tumor line with a bone marrow-derived macrophage. J Exp Med. 1984;160(5):1,579-84.
252. De Baetselier P, Roos E, Brys L, Remels L, Feldman M. Generation of invasive and metastatic variants of a non-metastatic T-cell lymphoma by in vivo fusion with normal host cells. Inter J Cancer. 1984;34(5):731-8.
253. Breier F, Feldmann R, Fellenz C, Neuhold N, Gschnait F. Primary invasive signet-ring cell melanoma. J Cutan Pathol. 1999;26(10):533-6.
254. Monteagudo C, Jorda E, Carda C, Illueca C, Peydro A, Llombart-Bosch A. Erythrophagocytic tumour cells in melanoma and squamous cell carcinoma of the skin. Histopathology. 1997;31(4):367-73.
255. Brocker EB, Suter L, Sorg C. HLA-DR antigen expression in primary melanomas of the skin. J Invest Dermatol. 1984;82(3):244-7.
256. Facchetti F, Bertalot G, Grigolato PG. KP1 (CD 68) staining of malignant melanomas. Histopathology. 1991;19(2):141-5.
257. Munzarova M, Rejthar A, Mechl Z. Do some malignant melanoma cells share antigens with the myeloid monocyte lineage? Neoplasma. 1991;38(4):401-5.
258. Savage DG, Zipin D, Bhagat G, Alobeid B. Hemophagocytic, non-secretory multiple myeloma. Leuk Lymphoma. 2004;45(5):1,061-4.
259. Andersen TL, Soe K, Sondergaard TE, Plesner T, Delaisse JM. Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells. Brit J Haematol.148(4):551-61.
260. Yasunaga M, Ohishi Y, Nishimura I, Tamiya S, Iwasa A, Takagi E, Inoue T, Yahata H, Kobayashi H, Wake N, Tsuneyoshi M. Ovarian undifferentiated carcinoma resembling giant cell carcinoma of the lung. Pathol Int. 2008;58(4):244-8.
261. Talmadge JE, Key ME, Hart IR. Characterization of a murine ovarian reticulum cell sarcoma of histiocytic origin. Cancer Res. 1981;41(4):1,271-80.
262. Kern HF, Bosslet K, Sedlacek HH, Schorlemmer HU. Monocyte-related functions expressed in cell lines established from human pancreatic adenocarcinoma. II. Inhibition of stimulated activity by monoclonal antibodies reacting with surface antigens on tumor cells. Pancreas. 1988;3(1):2-10.
263. Imai S, Sekigawa S, Ohno Y, Yamamoto H, Tsubura Y. Giant cell carcinoma of the pancreas. Acta Pathol Jpn. 1981;31(1):129-33.
264. Chetty R, Cvijan D. Giant (bizarre) cell variant of renal carcinoma. Histopathology. 1997;30(6):585-7.
265. Etcubanas E, Peiper S, Stass S, Green A. Rhabdomyosarcoma, presenting as disseminated malignancy from an unknown primary site: a retrospective study of ten pediatric cases. Med Pediatr Oncol. 1989;17(1):39-44.
266. Tsoi WC, Feng CS. Hemophagocytosis by rhabdomyosarcoma cells in bone marrow. Am J Hematol. 1997;54(4):340-2.
267. Matarrese P, Ciarlo L, Tinari A, Piacentini M, Malorni W. Xeno-cannibalism as an exacerbation of self-cannibalism: a possible fruitful survival strategy for cancer cells. Cur Pharma Design. 2008;14(3):245-52.
268. Overholtzer M, Brugge JS. The cell biology of cell-in-cell structures. Nat Rev Mol Cell Biol. 2008;9(10):796-809.
269. Gupta K, Dey P. Cell cannibalism: diagnostic marker of malignancy. Diag Cytopathol. 2003;28(2):86-7. Epub 2003/02/01.
270. Duelli D, Lazebnik Y. Cell-to-cell fusion as a link between viruses and cancer. Nature Rev Cancer. 2007;7(12):968-76